Tonix Teams Up with Top Vaccine Maker for Mpox Shot

This vaccine is built on a versatile technology platform that could be adapted to create recombinant versions for combating various other infectious diseases. Bilthoven Biologicals is renowned for its production of vaccines for both prophylactic and therapeutic purposes. The European Union has recognized Bilthoven Biologicals as a key player in its pandemic preparedness program, selecting it among the ‘ever warm’ vaccine manufacturing companies.

Animal studies have shown that TNX-801 offers immune protection with improved tolerability compared to older vaccines based on 20th-century vaccinia viruses. Preclinical trials have demonstrated that TNX-801 effectively protected non-human primates from lethal intratracheal Clade 1 mpox virus challenges.

After a single dose, TNX-801 prevented the onset of clinical disease, reduced lesions, and significantly decreased viral shedding in the mouth and lungs of the non-human primates. These results indicate the potential for mucosal immunity, which could block further transmission. On August 14, 2024, the World Health Organization declared the mpox surge in several African countries a public health emergency of international concern, marking the second such declaration in response to mpox outbreaks within two years.